NASDAQ:GNFT Genfit (GNFT) Stock Price, News & Analysis → Crypto Pioneer Says: “The last crypto bull market has begun.” (From InvestorPlace) (Ad) Free GNFT Stock Alerts $3.69 0.00 (0.00%) (As of 05/14/2024 ET) Add Compare Share Share Today's Range$3.69▼$3.7550-Day Range$3.40▼$3.8052-Week Range$2.89▼$4.75Volume3,809 shsAverage Volume13,253 shsMarket Capitalization$183.89 millionP/E RatioN/ADividend YieldN/APrice Target$11.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media Get Genfit alerts: Email Address Genfit MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside198.1% Upside$11.00 Price TargetShort InterestHealthy0.18% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.43Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom $0.56 to ($0.52) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.56 out of 5 starsMedical Sector2163rd out of 2,771 stocksBiological Products, Except Diagnostic Industry370th out of 462 stocks 3.5 Analyst's Opinion Consensus RatingGenfit has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageGenfit has only been the subject of 1 research reports in the past 90 days.Read more about Genfit's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.18% of the float of Genfit has been sold short.Short Interest Ratio / Days to CoverGenfit has a short interest ratio ("days to cover") of 14.7, which indicates bearish sentiment.Change versus previous monthShort interest in Genfit has recently decreased by 5.78%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldGenfit does not currently pay a dividend.Dividend GrowthGenfit does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for GNFT. Previous Next 3.0 News and Social Media Coverage News SentimentGenfit has a news sentiment score of 1.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.57 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Genfit this week, compared to 0 articles on an average week. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Genfit insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.20% of the stock of Genfit is held by insiders.Percentage Held by InstitutionsOnly 2.24% of the stock of Genfit is held by institutions.Read more about Genfit's insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Genfit are expected to decrease in the coming year, from $0.56 to ($0.52) per share.Price to Book Value per Share RatioGenfit has a P/B Ratio of 2.49. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Genfit's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Paradigm PressBiden FINISHED On June 13th?Thanks to Biden’s disgraceful leadership we now have sky-high inflation… unchecked immigration… rampant crime… and a “woke mob” hell bent on destroying the America you and I know and love. Biden’s days are numbered.Click here now to see his shocking evidence. About Genfit Stock (NASDAQ:GNFT)Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.Read More GNFT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GNFT Stock News HeadlinesMay 14 at 4:10 PM | globenewswire.comGENFIT Reports First Quarter 2024 Financial InformationApril 25, 2024 | globenewswire.comGENFIT: Publication of the 2024 Extra-Financial Performance Report (fiscal year 2023)April 15, 2024 | globenewswire.comGENFIT Annual Combined General Meeting of May 22, 2024 — Availability of Preparatory DocumentsApril 5, 2024 | globenewswire.comGENFIT Announces Publication of the 2023 Universal Registration Document and the 2023 Annual Report on Form 20-FApril 5, 2024 | finanznachrichten.deGENFIT S.A.: GENFIT Reports Full-Year 2023 Financial Results and Provides Corporate UpdateApril 4, 2024 | globenewswire.comGENFIT Reports Full-Year 2023 Financial Results and Provides Corporate UpdateApril 3, 2024 | msn.comEuropean Equities Traded in the US as American Depositary Receipts Trend Higher in Wednesday TradingMarch 27, 2024 | msn.comEuropean Equities Traded in the US as American Depositary Receipts Rise Slightly in Wednesday TradingFebruary 29, 2024 | globenewswire.comGENFIT Announces Revenues and Cash Position as of December 31, 2023February 25, 2024 | thestreet.comGENFIT S.A.February 16, 2024 | msn.comInventiva drops after adverse event in Phase 3 trial for NASH drugFebruary 5, 2024 | msn.comEuropean Equities Traded in the US as American Depositary Receipts Kick Off Week Lower in Monday TradingJanuary 29, 2024 | msn.comEuropean Equities Traded in the US as American Depositary Receipts Trend Lower in Monday TradingDecember 21, 2023 | benzinga.comGenfit Stock (NASDAQ:GNFT) Dividends: History, Yield and DatesDecember 20, 2023 | morningstar.comGenfit SA ADR GNFTDecember 7, 2023 | msn.comFDA grants priority review of Genfit-Ipsen liver disease drugDecember 7, 2023 | markets.businessinsider.comIpsen confirms U.S. FDA grants priority review for New Drug Application for elafibranor for the treatment of rare cholestatic liver disease, PBCNovember 17, 2023 | benzinga.comGENFIT Highlights ACLF Development Strategy at "ACLF Day" during AASLD The Liver Meeting® 2023November 9, 2023 | finance.yahoo.comGENFIT Reports Third Quarter 2023 Financial InformationNovember 9, 2023 | msn.comOil Stocks Buoy European Equities Traded in the US as American Depositary Receipts ThursdayNovember 7, 2023 | msn.comOil Stocks Burden European Equities Traded in the US as American Depositary Receipts TuesdaySeptember 26, 2023 | finance.yahoo.comGENFIT Announces Publication in Nature Medicine Confirming the Performance of its NASH Diagnostic TechnologySeptember 26, 2023 | finance.yahoo.comGENFIT S.A. Unsponsored ADR (GNFT) May Find a Bottom Soon, Here's Why You Should Buy the Stock NowSeptember 22, 2023 | finanznachrichten.deGENFIT S.A.: GENFIT Reports First Half-Year 2023 Financial Results and Provides Corporate UpdateSeptember 20, 2023 | finance.yahoo.comGENFIT Reports First Half-Year 2023 Financial Results and Provides Corporate UpdateSee More Headlines Receive GNFT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Genfit and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today5/14/2024Next Earnings (Estimated)7/04/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:GNFT CUSIPN/A CIK1757064 Webwww.genfit.com Phone(332) 016-4000FaxN/AEmployees159Year FoundedN/APrice Target and Rating Average Stock Price Target$11.00 High Stock Price Target$11.00 Low Stock Price Target$11.00 Potential Upside/Downside+198.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.92 Current Ratio2.94 Quick Ratio2.94 Sales & Book Value Annual Sales$41.31 million Price / Sales4.45 Cash FlowN/A Price / Cash FlowN/A Book Value$1.48 per share Price / Book2.49Miscellaneous Outstanding Shares49,830,000Free Float47,742,000Market Cap$183.87 million OptionableNot Optionable Beta1.06 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesMr. Jean-Francois Mouney (Age 69)Co-Founder & Chairman of the Board Comp: $383.03kMr. M. Pascal Prigent (Age 55)Chief Executive Officer Comp: $594.96kProf. Bart Staels (Age 61)Co-Founder & Chairman of the Scientific Advisory Board Mr. Thomas Baetz (Age 49)Chief Financial Officer Mr. Pascal Caisey (Age 55)Chief Operating Officer Dr. Meriam Kabbaj Ph.D. (Age 50)Chief Technology Officer Dr. Dean W. Hum Ph.D. (Age 62)Chief Scientific Officer Comp: $758.26kMr. Jean-Christophe Marcoux (Age 46)Chief Corporate Affairs Officer, Head of Investor Relations & Head of ESG Mr. Laurent Lannoo (Age 53)Corporate Secretary & Director of Legal Affairs Ms. Stefanie Magner J.D. (Age 42)Chief Compliance Officer & Executive VP of International Legal Affairs More ExecutivesKey CompetitorsCellectisNASDAQ:CLLSX4 PharmaceuticalsNASDAQ:XFOR10X Capital Venture Acquisition Corp. IIINYSE:VCXBElevation OncologyNASDAQ:ELEVCompugenNASDAQ:CGENView All Competitors GNFT Stock Analysis - Frequently Asked Questions Should I buy or sell Genfit stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Genfit in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" GNFT shares. View GNFT analyst ratings or view top-rated stocks. What is Genfit's stock price target for 2024? 1 brokers have issued twelve-month price targets for Genfit's shares. Their GNFT share price targets range from $11.00 to $11.00. On average, they anticipate the company's share price to reach $11.00 in the next twelve months. This suggests a possible upside of 198.1% from the stock's current price. View analysts price targets for GNFT or view top-rated stocks among Wall Street analysts. How have GNFT shares performed in 2024? Genfit's stock was trading at $3.85 at the beginning of the year. Since then, GNFT stock has decreased by 4.2% and is now trading at $3.69. View the best growth stocks for 2024 here. When is Genfit's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, July 4th 2024. View our GNFT earnings forecast. What is Jean-François Mouney's approval rating as Genfit's CEO? 3 employees have rated Genfit Chief Executive Officer Jean-François Mouney on Glassdoor.com. Jean-François Mouney has an approval rating of 29% among the company's employees. This puts Jean-François Mouney in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Genfit own? Based on aggregate information from My MarketBeat watchlists, some companies that other Genfit investors own include Intercept Pharmaceuticals (ICPT), InterDigital (IDCC), STAG Industrial (STAG), Gilead Sciences (GILD), Occidental Petroleum (OXY), Vaxart (VXRT), Exxon Mobil (XOM), Zynerba Pharmaceuticals (ZYNE), Aimmune Therapeutics (AIMT) and Amarin (AMRN). When did Genfit IPO? Genfit (GNFT) raised $132 million in an IPO on Wednesday, March 27th 2019. The company issued 5,000,000 shares at $26.33 per share. SVB Leerink and Barclays acted as the underwriters for the IPO and Bryan, Garnier, Natixis, Roth Capital Partners and H.C. Wainwright & Co. were co-managers. How do I buy shares of Genfit? Shares of GNFT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:GNFT) was last updated on 5/14/2024 by MarketBeat.com Staff From Our PartnersDid Intel Just Dethrone Nvidia?Chaikin AnalyticsClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsCharles Payne Demystifies OptionsUnstoppable ProsperityThe only AI company you should be looking atBehind the MarketsTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressRevolutionizing the Green Energy Space and Building Shareholder Value Along the WaySmall Cap SniperElon to Transform U.S. Economy? Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genfit S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.